8-K Announcements
6Material company update
Apr 15, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Apr 13, 2026·SEC
Allogene Therapeutics, Inc.(ALLO)Earnings, Financials & Key Ratios
ALLO•NASDAQ
$2.31
$530M mkt cap·Price updated May 6, 2026
AboutAllogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Show more
- Revenue$0-100.0%
- EBITDA-$209M+19.4%
- Net Income-$191M+25.9%
- EPS (Diluted)-0.87+34.1%
- ROE-53.42%+3.1%
- ROIC-41.66%+2.2%
- Debt/Equity0.26+19.3%
ALLO Key Insights
Allogene Therapeutics, Inc. (ALLO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 85 (top 15%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 13.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ALLO Price & Volume
Allogene Therapeutics, Inc. (ALLO) stock price & volume — 10-year historical chart
Loading chart...
ALLO Growth Metrics
Allogene Therapeutics, Inc. (ALLO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM25.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM34.59%
Return on Capital
10 Years-35.01%
5 Years-39.6%
3 Years-47.75%
Last Year-46.69%
ALLO Recent Earnings
Allogene Therapeutics, Inc. (ALLO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (100%)
Q2 2026Latest
Mar 12, 2026EPS
$0.17
Est $0.25
+32.0%
Revenue
—
Est $2,500
Q4 2025
Nov 6, 2025EPS
$0.19
Est $0.23
+17.4%
Revenue
—
Est $1,820
Q3 2025
Aug 13, 2025EPS
$0.23
Est $0.28
+17.9%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.28
Est $0.28
+0.0%
Revenue
—
Est $1,670
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.17vs $0.25+32.0% | —vs $2,500 |
| Q4 2025 | Nov 6, 2025 | $0.19vs $0.23+17.4% | —vs $1,820 |
| Q3 2025 | Aug 13, 2025 | $0.23vs $0.28+17.9% | — |
| Q2 2025 | May 13, 2025 | $0.28vs $0.28+0.0% | —vs $1,670 |
Based on last 12 quarters of dataView full earnings history →
ALLO Peer Comparison
Allogene Therapeutics, Inc. (ALLO) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 CELH | 8.43B | 32.80 | 131.20 | 85.54% | 4.29% | 4.66% | 0.23 | |
 CABA | 381.44M | 3.73 | -2.27 | -121.73% | 0.24 | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 |
Compare ALLO vs Peers
Allogene Therapeutics, Inc. (ALLO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALLO Income Statement
Allogene Therapeutics, Inc. (ALLO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 114.09M | 156K | 95K | 22K | 0 |
| Revenue Growth % | - | - | - | - | - | -99.86% | -39.1% | -76.84% | -100% |
| Cost of Goods Sold | 0 | 0 | 5.03M | 11.54M | 0 | 14.29M | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | 9163.46% | - | - | - |
| Gross Profit | 0▲ 0% | -1.5M▲ 0% | -5.03M▼ 235.1% | -11.54M▼ 129.6% | 114.09M▲ 1088.6% | -14.14M▼ 112.4% | 95K▲ 100.7% | 22K▼ 76.8% | 0▼ 100.0% |
| Gross Margin % | - | - | - | - | 100% | -9063.46% | 100% | 100% | - |
| Gross Profit Growth % | - | - | -235.13% | -129.58% | 1088.55% | -112.39% | 100.67% | -76.84% | -100% |
| Operating Expenses | 2K | 192.84M | 202.01M | 246.7M | 294.28M | 321.4M | 327.83M | 273.22M | 209.31M |
| OpEx % of Revenue | - | - | - | - | 257.94% | 206023.72% | 345086.32% | 1241913.64% | - |
| Selling, General & Admin | 2K | 40.98M | 57.47M | 65.26M | 74.11M | 79.31M | 71.67M | 65.2M | 56.78M |
| SG&A % of Revenue | - | - | - | - | 64.95% | 50836.54% | 75445.26% | 296386.36% | - |
| Research & Development | 0 | 151.86M | 144.53M | 192.99M | 220.18M | 256.39M | 242.91M | 192.3M | 150.15M |
| R&D % of Revenue | - | - | - | - | 192.99% | 164350.64% | 255698.95% | 874086.36% | - |
| Other Operating Expenses | 0 | 0 | 0 | -11.54M | 0 | -14.29M | 13.24M | 15.72M | 2.38M |
| Operating Income | -2K▲ 0% | -192.84M▼ 9642000.0% | -202.01M▼ 4.8% | -258.24M▼ 27.8% | -180.19M▲ 30.2% | -335.54M▼ 86.2% | -327.74M▲ 2.3% | -273.2M▲ 16.6% | -209.31M▲ 23.4% |
| Operating Margin % | - | - | - | - | -157.94% | -215087.18% | -344986.32% | -1241813.64% | - |
| Operating Income Growth % | - | -9642000% | -4.75% | -27.84% | 30.22% | -86.21% | 2.32% | 16.64% | 23.38% |
| EBITDA | 22K | -191.34M | -196.98M | -246.7M | -169.74M | -321.24M | -313.54M | -259.56M | -209.31M |
| EBITDA Margin % | - | - | - | - | -148.78% | -205923.72% | -330040% | -1179818.18% | - |
| EBITDA Growth % | - | -869836.36% | -2.95% | -25.24% | 31.2% | -89.26% | 2.4% | 17.22% | 19.36% |
| D&A (Non-Cash Add-back) | 24K | 1.5M | 5.03M | 11.54M | 10.45M | 14.29M | 14.2M | 13.64M | 0 |
| EBIT | -2K | -208.26M | -184.93M | -250.22M | -180.19M | -335.54M | -327.26M | -256.97M | 0 |
| Net Interest Income | 0 | 2.43M | 17.35M | 9.16M | 1.71M | 4.57M | 18.31M | 19.97M | 0 |
| Interest Income | 0 | 5.79M | 17.35M | 9.16M | 1.71M | 4.57M | 18.31M | 20.15M | 0 |
| Interest Expense | 0 | 3.36M | 0 | 0 | 0 | 0 | 0 | 181K | -1.07M |
| Other Income/Expense | 0 | -18.78M | 17.08M | 8.02M | -1.86M | -4.88M | 472K | 16.05M | 18.43M |
| Pretax Income | -24K▲ 0% | -211.62M▼ 881658.3% | -184.93M▲ 12.6% | -250.22M▼ 35.3% | -182.05M▲ 27.2% | -340.41M▼ 87.0% | -327.26M▲ 3.9% | -257.15M▲ 21.4% | -190.89M▲ 25.8% |
| Pretax Margin % | - | - | - | - | -159.57% | -218214.1% | -344489.47% | -1168850% | - |
| Income Tax | -24K | -117K | -331K | 0 | 0 | 0 | 0 | 443K | 0 |
| Effective Tax Rate % | 100% | 0.06% | 0.18% | 0% | 0% | 0% | 0% | -0.17% | 0% |
| Net Income | -2K▲ 0% | -211.5M▼ 10575150.0% | -184.59M▲ 12.7% | -250.22M▼ 35.6% | -182.05M▲ 27.2% | -340.41M▼ 87.0% | -327.26M▲ 3.9% | -257.59M▲ 21.3% | -190.89M▲ 25.9% |
| Net Margin % | - | - | - | - | -159.57% | -218214.1% | -344489.47% | -1170863.64% | - |
| Net Income Growth % | - | -10575150% | 12.72% | -35.55% | 27.24% | -86.99% | 3.86% | 21.29% | 25.9% |
| Net Income (Continuing) | -2K | -211.5M | -184.59M | -250.22M | -182.05M | -340.41M | -327.26M | -257.59M | -190.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00▲ 0% | -2.36▲ 0% | -1.83▲ 22.5% | -2.08▼ 13.7% | -1.34▲ 35.6% | -2.38▼ 77.6% | -2.09▲ 12.2% | -1.32▲ 36.8% | -0.87▲ 34.1% |
| EPS Growth % | - | - | 22.46% | -13.66% | 35.58% | -77.61% | 12.18% | 36.84% | 34.09% |
| EPS (Basic) | 0.00 | -2.36 | -1.83 | -2.08 | -1.34 | -2.38 | -2.09 | -1.32 | -0.87 |
| Diluted Shares Outstanding | 44.01M | 89.69M | 101.06M | 120.37M | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
| Basic Shares Outstanding | 44.01M | 89.69M | 101.06M | 120.37M | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ALLO Balance Sheet
Allogene Therapeutics, Inc. (ALLO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 0 | 467.98M | 544.58M | 845.13M | 471.32M | 528.82M | 459.12M | 303.39M | 257.75M |
| Cash & Short-Term Investments | 0 | 721.35M | 530.53M | 827.91M | 457.3M | 517.32M | 448.7M | 292.48M | 250.21M |
| Cash Only | 0 | 721.35M | 175.13M | 183.35M | 173.31M | 61.9M | 83.16M | 75.22M | 51.69M |
| Short-Term Investments | 0 | 0 | 355.41M | 644.56M | 283.99M | 455.42M | 365.54M | 217.26M | 198.52M |
| Accounts Receivable | 0 | 3.11M | 2.4M | 0 | 0 | 0 | 1.7M | 1.9M | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | 6.53K | 31.52K | - |
| Inventory | 0 | -261.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | -2.4M | 0 | 0 | 11.5M | 0 | 9.01M | 7.54M |
| Total Non-Current Assets | 0 | 305.87M | 173.23M | 382.7M | 579.5M | 292.75M | 183.72M | 245.32M | 158.16M |
| Property, Plant & Equipment | 0 | 41.61M | 100.94M | 160.13M | 181.02M | 196.43M | 163.18M | 131.26M | 112.73M |
| Fixed Asset Turnover | - | - | - | - | 0.63x | 0.00x | 0.00x | 0.00x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 754K | 151K | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 261.97M | 63.21M | 207.95M | 382.38M | 76.47M | 3.65M | 80.67M | 8.04M |
| Other Non-Current Assets | 0 | 1.54M | 8.92M | 14.62M | 16.11M | 19.86M | 16.9M | 33.39M | 37.39M |
| Total Assets | 0▲ 0% | 773.86M▲ 0% | 717.8M▼ 7.2% | 1.23B▲ 71.1% | 1.05B▼ 14.4% | 821.58M▼ 21.8% | 642.84M▼ 21.8% | 548.71M▼ 14.6% | 415.9M▼ 24.2% |
| Asset Turnover | - | - | - | - | 0.11x | 0.00x | 0.00x | 0.00x | - |
| Asset Growth % | - | - | -7.24% | 71.05% | -14.42% | -21.82% | -21.76% | -14.64% | -24.2% |
| Total Current Liabilities | 2K | 29.46M | 33.08M | 94.32M | 47.91M | 53.73M | 37.08M | 35.52M | 32.51M |
| Accounts Payable | 0 | 12.34M | 9.25M | 10.39M | 10.26M | 13.89M | 5.9M | 5.39M | 4.27M |
| Days Payables Outstanding | - | - | 671.62 | 328.6 | - | 354.66 | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 38.99M | 156K | 95K | 86K | 0 | 0 |
| Other Current Liabilities | 0 | 5.2M | 12.4M | 12.97M | 16.13M | 17.93M | 11.66M | 12.15M | 32.51M |
| Current Ratio | - | 15.89x | 16.46x | 8.96x | 9.84x | 9.84x | 12.38x | 8.54x | 7.93x |
| Quick Ratio | - | 24.78x | 16.46x | 8.96x | 9.84x | 9.84x | 12.38x | 8.54x | 7.93x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 41.23M | 55.7M | 53.89M | 77.72M | 100.97M | 93.53M | 91.01M | 90.85M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75.05M |
| Capital Lease Obligations | 0 | 34.46M | 51.35M | 50.81M | 69.93M | 95.12M | 88.35M | 83.25M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 6.78M | 4.35M | 3.08M | 7.79M | 5.85M | 5.18M | 7.76M | 15.8M |
| Total Liabilities | 2K | 70.69M | 88.78M | 148.21M | 125.63M | 154.7M | 130.6M | 126.53M | 123.36M |
| Total Debt | 0 | 34.46M | 53.03M | 53.78M | 73.13M | 101.12M | 95.12M | 90.76M | 75.05M |
| Net Debt | 0 | -686.89M | -122.1M | -129.57M | -100.19M | 39.22M | 11.97M | 15.54M | 23.36M |
| Debt / Equity | - | 0.05x | 0.08x | 0.05x | 0.08x | 0.15x | 0.19x | 0.21x | 0.26x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -57.43x | - | - | - | - | - | -1509.39x | - |
| Total Equity | -2K▲ 0% | 703.16M▲ 35158300.0% | 629.02M▼ 10.5% | 1.08B▲ 71.6% | 925.2M▼ 14.3% | 666.88M▼ 27.9% | 512.23M▼ 23.2% | 422.18M▼ 17.6% | 292.54M▼ 30.7% |
| Equity Growth % | - | 35158300% | -10.54% | 71.63% | -14.3% | -27.92% | -23.19% | -17.58% | -30.71% |
| Book Value per Share | -0.00 | 7.84 | 6.22 | 8.97 | 6.81 | 4.66 | 3.26 | 2.17 | 1.33 |
| Total Shareholders' Equity | -2K | 703.16M | 629.02M | 1.08B | 925.2M | 666.88M | 512.23M | 422.18M | 292.54M |
| Common Stock | 26K | 121K | 124K | 140K | 142K | 144K | 169K | 212K | 229K |
| Retained Earnings | -23K | -211.53M | -396.12M | -646.34M | -894.55M | -1.23B | -1.56B | -1.82B | -2.01B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5K | 306K | 1.15M | 268K | -2.57M | -9.93M | -955K | -89K | 269K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALLO Cash Flow Statement
Allogene Therapeutics, Inc. (ALLO) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 0 | -44.65M | -137.35M | -115.09M | -184.81M | -220.52M | -237.73M | -200.3M | -149.25M |
| Operating CF Margin % | - | - | - | - | -161.99% | -141358.33% | -250245.26% | -910454.55% | - |
| Operating CF Growth % | - | - | -207.59% | 16.2% | -60.58% | -19.32% | -7.81% | 15.75% | 25.49% |
| Net Income | -24K | -211.5M | -184.59M | -250.22M | -257M | -332.63M | -327.26M | -257.59M | -190.89M |
| Depreciation & Amortization | 0 | 1.5M | 5.03M | 7.59M | 10.45M | 14.29M | 14.2M | 13.64M | 12.36M |
| Stock-Based Compensation | 0 | 18.57M | 46.06M | 65.26M | 80.82M | 83.6M | 65.95M | 51.74M | 37.64M |
| Deferred Taxes | 0 | -117K | -331K | 4.4M | 10.4M | 8.08M | 0 | 443K | 0 |
| Other Non-Cash Items | 0 | 134.81M | 3.36M | 3.96M | 2.61M | 2.43M | 24.69M | 16.26M | -8.36M |
| Working Capital Changes | 24K | 12.1M | -6.88M | 53.92M | -32.09M | 3.71M | -15.3M | -24.8M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 8.8M | -985K | 615K | -767K | 4.87M | -7.5M | -503K | -1.23M |
| Cash from Investing | 0 | -632.8M | 164.08M | -505.12M | 163.66M | 106.16M | 163.29M | 75.69M | 95.56M |
| Capital Expenditures | 0 | -3.23M | -50.79M | -65.96M | -21.45M | -5.19M | -1.52M | -694K | -386K |
| CapEx % of Revenue | - | - | - | - | 18.8% | 3327.56% | 1595.79% | 3154.55% | - |
| Acquisitions | 0 | 0 | -5.08M | 439.17M | -17.71M | -111.35M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -2.1M | 0 | -439.17M | 0 | 111.35M | 0 | 0 | 0 |
| Cash from Financing | 0 | 771.18M | 58.96M | 633.59M | 11.96M | 2.95M | 95.69M | 116.67M | 30.16M |
| Debt Issued (Net) | 0 | 116.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 895K |
| Other Financing | 0 | 654.34M | 4.74M | 11.66M | 0 | 0 | 4.58M | 2.28M | 30.16M |
| Net Change in Cash | 0▲ 0% | 93.73M▲ 0% | 85.69M▼ 8.6% | 13.38M▼ 84.4% | -9.19M▼ 168.7% | -111.41M▼ 1111.8% | 21.25M▲ 119.1% | -7.94M▼ 137.3% | -23.53M▼ 196.5% |
| Free Cash Flow | 0▲ 0% | -47.89M▲ 0% | -188.14M▼ 292.9% | -181.05M▲ 3.8% | -206.26M▼ 13.9% | -225.71M▼ 9.4% | -239.25M▼ 6.0% | -200.99M▲ 16.0% | -149.63M▲ 25.6% |
| FCF Margin % | - | - | - | - | -180.79% | -144685.9% | -251841.05% | -913609.09% | - |
| FCF Growth % | - | - | -292.89% | 3.77% | -13.92% | -9.43% | -6% | 15.99% | 25.55% |
| FCF per Share | - | -0.53 | -1.86 | -1.50 | -1.52 | -1.58 | -1.52 | -1.03 | -0.68 |
| FCF Conversion (FCF/Net Income) | - | 0.21x | 0.74x | 0.46x | 1.02x | 0.65x | 0.73x | 0.78x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALLO Key Ratios
Allogene Therapeutics, Inc. (ALLO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -60.16% | -27.71% | -29.29% | -18.16% | -42.76% | -55.51% | -55.13% | -53.42% |
| Return on Invested Capital (ROIC) | - | -1778.11% | -57.92% | -26.59% | -15.23% | -32.87% | -39.96% | -42.6% | -41.66% |
| Gross Margin | - | - | - | - | 100% | -9063.46% | 100% | 100% | - |
| Net Margin | - | - | - | - | -159.57% | -218214.1% | -344489.47% | -1170863.64% | - |
| Debt / Equity | - | 0.05x | 0.08x | 0.05x | 0.08x | 0.15x | 0.19x | 0.21x | 0.26x |
| Interest Coverage | - | -57.43x | - | - | - | - | - | -1509.39x | - |
| FCF Conversion | - | 0.21x | 0.74x | 0.46x | 1.02x | 0.65x | 0.73x | 0.78x | 0.78x |
| Revenue Growth | - | - | - | - | - | -99.86% | -39.1% | -76.84% | -100% |
ALLO SEC Filings & Documents
Allogene Therapeutics, Inc. (ALLO) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALLO Frequently Asked Questions
Allogene Therapeutics, Inc. (ALLO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Allogene Therapeutics, Inc. (ALLO) saw revenue decline by 100.0% over the past year.
Allogene Therapeutics, Inc. (ALLO) reported a net loss of $190.9M for fiscal year 2025.
Dividend & Returns
Allogene Therapeutics, Inc. (ALLO) has a return on equity (ROE) of -53.4%. Negative ROE indicates the company is unprofitable.
Allogene Therapeutics, Inc. (ALLO) had negative free cash flow of $149.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More ALLO
Allogene Therapeutics, Inc. (ALLO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates